ORA™ is launching NEPTIS® Designer, a revolutionary tool for tracers development, during EANM 2016

Philippeville, Belgium, October 15th 2016 / Optimized Radiochemical Applications (ORA™) today announced the effective launch and availability of its new NEPTIS® Designer application software, a revolutionary 3D virtual reality tool for the development of new tracers.

With the market evolution of PET tracers, the new challenge, especially for academics and researchers, is how to be able to test and implement new tracers, seamlessly and efficiently on a variety of synthesizer platforms. Until today, there was no easy and standalone tool available to achieve this goal. By using the latest technology in software development, it was possible to elaborate this very desirable critical tool.

NEPTIS® Designer application software allows the development of customized syntheses with their associated graphical reaction pathway in a standalone environment, and the export of the complete tracer application for immediate operation with the NEPTIS® synthesizers. This tool brings invaluable flexibility in assisting in the development of any type of synthesis including graphical definition of the cassette hardware, associated cassette testing sequence, assistance to build up a pre-validated synthesis sequence, and running and fine tuning them.
NEPTIS_DesignerWith its new NEPTIS® Designer application, ORA aims to unleash the creativity of the radiochemistry researchers around the world. Therefore, ORA is providing an entirely free research license of NEPTIS® Designer against a simple registration form available on its website.

This new software application will help the users to get the most out their NEPTIS® synthesizers, the already widest available range on the market place today: NEPTIS® perform, NEPTIS® Nx3,  NEPTIS® mosaic-RS and NEPTIS® mosaic-LC.

ORA™ is demonstrating its new NEPTIS® Designer application software at booth number #21 at the European Society of Nuclear Medicine annual meeting from 16 to 18 October 2016 in Barcelona, Spain.

NEPTIS® synthesizers, dedicated for the production of PET radiopharmaceuticals, aimed since their inceptions to address the various challenges, different by nature, of personalized medicine, a young but rapidly advancing field of healthcare: restoring freedom for researchers with an open and flexible freedom, providing developers with a robust tool from clinical trials to commercial production, and offering producers a guarantee or reliable and repetitive performance. Additional information about NEPTIS® is available at www.neptis-vsa.com.

About Optimized Radiochemical Applications (ORA™)
ORA, an innovation-driven Belgian company based founded in 2006, is developing an extensive range of PET synthesizers for existing and new radiopharmaceuticals and collaborates with major research institutions and pharmaceutical companies worldwide. Additional information about ORA is available at www.oradiochem.eu.

©ORA Belgium, 2015. All rights reserved. PR161015
NEPTIS® is a trademark of ORA™

For immediate release

Contact: Vincent Tadino
Phone: (0032) 71 61 40 53
Email: info@oradiochem.eu

Print Friendly, PDF & Email